PD-1／PD—L1通路在非小细胞肺癌中的研究进展

Progression of PD-1/PD-L1 pathway in non-small cell lung cancer

程序性死亡受体-1（PD-1）／程序性死亡配体1（PD-L1）信号途径参与肿瘤的免疫逃逸。PD-L1蛋白在非小细胞肺癌组织中存在不同程度的表达，其表达程度与肿瘤细胞的分化程度、临床分期、淋巴转移及预后等相关联。PD-L1可能通过保持非小细胞肺癌肿瘤浸润性树突状细胞的不成熟状态，增强调节性T细胞功能，与浸润性淋巴细胞表面高表达的PD-1相互作用诱导CD8＋T细胞凋亡等机制介导肺癌的免疫豁免。目前针对PD-1／PD-L1途径的临床免疫治疗试验已经在非小细胞肺癌中取得一定的疗效，成为非小细胞肺癌免疫治疗的新靶向。

The programmed death receptor-1（PD-1）/programmed death ligand-1（PD-L1） signaling pathway involves in tumor immune escape. The level of PD-L1 is different in non-small cell lung cancer, the expression of PD-L1 may be associated with the degree of tumor cell differentiation, clinical stage, lymph node metastasis, and prognosis. Expression of PD-L1 in non-small cell lung cancer mediate immune function exemption by remaining immature state of tumor-infiltrating dendritic cells, enhancing the function of regulatory T cells, and inducing CD8＋ T cell apoptosis through interaction with PD-1 highly expressed on infiltrating lymphocyte surface and other mechanisms. Currently immunotherapy clinical trials for PD-1/PD-L1 pathway has already achieved certain effect in non-small cell lung cancer,becoming the new target for immunotherapy.